Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | RXRA | P19793 | 6/20 | 0.48 |
| ▸ | RXRB | P28702 | 6/20 | 0.48 |
| ▸ | RXRG | P48443 | 6/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24208571 | 0.95 | HDAC4 (0.57) | HDAC4HDAC6RXRARXRBRXRG | |
| SCHEMBL25384379 | 0.90 | HDAC4 (0.53) | HDAC4HDAC6KCNH2MAPK8MAPK10 | |
| SCHEMBL30357689 | 0.86 | HDAC4 (0.49) | HDAC4HDAC6KCNH2MAPK8MAPK10 | |
| SCHEMBL4692646 | 0.81 | HDAC4 (0.49) | HDAC4HDAC6RXRARXRBRXRG | |
| SCHEMBL1515926 | 0.81 | LMNA (0.55) | HDAC4HDAC6 | |
| SCHEMBL3737479 | 0.81 | FFAR1 (0.46) | HDAC4HDAC6 | |
| SCHEMBL12002541 | 0.80 | HDAC4 (0.51) | HDAC4HDAC6 | |
| SCHEMBL18388186 | 0.79 | HDAC4 (0.54) | HDAC4HDAC6KCNH2MAPK8MAPK10 | |
| SCHEMBL14477117 | 0.78 | CYP4F2 (0.53) | RXRARXRBRXRGMAPK8MAPK10 | |
| SCHEMBL4087349 | 0.78 | MEN1 (0.50) | HDAC4HDAC6OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989457-B2 | Used to treat diabetic and other glucagon related metabolic disorders such as obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing; (R,S)-Methanesulfonic acid 2-(3-methyl-4'-trifluoromethyl-biphenyl-4-yl)-propyl ester | ELI LILLY AND COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-05-29 | — | — | US | disclosed |
| EP-1758859-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005118542-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | HDAC4 4133/4885HDAC6 3745/4885RXRA 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.